Research advances in primary biliary cholangitis with hyperlipidemia
DOI:10.3969/j.issn.1001-5256.2021.01.049
- VernacularTitle:原发性胆汁性胆管炎并发高脂血症的研究现状
- Author:
Lina FENG
1
;
Xiaoxue ZHANG
;
Jianjie HUANG
;
Bo MA
;
Xiaoyu WEN
;
Manqiu CHEN
;
Qinglong JIN
Author Information
1. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Research Article
- Keywords:
Liver Cirrhosis， Biliary;
Hyperlipidemia;
Hypercholesterolemia
- From:
Journal of Clinical Hepatology
2021;37(1):221-224
- CountryChina
- Language:Chinese
-
Abstract:
Dyslipidemia is one of the most common complications of primary biliary cholangitis (PBC). This article reviews the latest research on lipid profile, the risk of cardiovascular diseases, and treatment of PBC with hyperlipidemia. Different from other liver diseases, PBC with hyperlipidemia has a unique lipid profile, which changes dynamically with disease progression. It is generally not considered that there are increased risks of atherosclerosis and cardiovascular disease. For those who have indications for treatment, statins are recommended as the first choice. In the future, more in-depth systematic studies are needed to clarify its diagnosis, treatment, and management processes.
